Cgp 6809

Notice: hodoodo.ccom website will be shut down by June 30, 2025. Its business will be taken care by MedKoo Bioscience. Please visit medkoo.com for your research need.

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H524647

CAS#: 84069-38-5

Description: Cgp 6809 is a new methylnitrosoureido-sugar derivative that has been shown to be active against a broad spectrum of transplantable tumours in mice and rats. CGP 6809 is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer.

Chemical Structure

img
Cgp 6809
CAS# 84069-38-5
Instruction

Theoretical Analysis

Hodoodo Cat#: H524647
Name: Cgp 6809
CAS#: 84069-38-5
Chemical Formula: C12H23N3O7
Exact Mass: 321.15
Molecular Weight: 321.330
Elemental Analysis: C, 44.85; H, 7.21; N, 13.08; O, 34.85

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Cgp 6809; Cgp6809; Cgp-6809.

IUPAC/Chemical Name: Ethyl-6-deoxy-3,5-di-O-methyl-6-(3-methyl-3-nitrosoureido)glucofuranoside

InChi Key: DRYAELVKAAODIB-ILAIQSSSSA-N

InChi Code: InChI=1S/C12H23N3O7/c1-5-21-11-8(16)10(20-4)9(22-11)7(19-3)6-13-12(17)15(2)14-18/h7-11,16H,5-6H2,1-4H3,(H,13,17)/t7-,8-,9-,10-,11+/m1/s1

SMILES Code: O([C@@H]([C@@H]1[C@H](OC)[C@@H](O)[C@H](O1)OCC)CNC(N(N=O)C)=O)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 321.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Creaven PJ, Cowens JW, Huben R, Petrelli N, Karakousis C, Traynor D. Phase I trial of a new nitrosourea, CGP 6809, given every 2 weeks. Cancer Chemother Pharmacol. 1989;23(4):266-7. PubMed PMID: 2924383.

2: Schieweck K, Stanek J, Kanter PM, Schmidt-Ruppin KH, Müller M, Matter A. CGP 6809, a sugar-containing nitrosourea derivative: pharmacological and physicochemical properties. Cancer Chemother Pharmacol. 1989;23(6):341-7. PubMed PMID: 2713956.

3: Fiebig HH, Widmer KH, Winterhalter BR, Löhr GW. CGP 6809--a new nitrosoureido-sugar derivative with activity in human tumor xenografts. Cancer Chemother Pharmacol. 1989;23(6):337-40. PubMed PMID: 2713955.

4: Creaven PJ, Madajewicz S, Cowens JW, Plager JE, Pendyala L, Mittelman A, Petrelli N, Karakousis C, Huben R, Takita H, et al. Phase I clinical trial of ethyl 6-deoxy-3,5-di-O-methyl 6-(3 methyl-3-nitrosoureido)-alpha-D-glucofuranoside (CGP 6809). Cancer Chemother Pharmacol. 1987;20(1):37-40. PubMed PMID: 3304687.

5: Bernacki RJ, Wilson GL, Mossman BT, Angelino N, Kanter PM, Korytnyk W. Therapeutic and diabetogenic potential of two newly synthesized nitrosoureido sugars. Cancer Res. 1985 Feb;45(2):695-702. PubMed PMID: 3881170.

6: Wagner I, Habs M, Schmähl D, Amberger H, Bachmann U. Chemotherapeutic studies on N-nitrosoacetoxymethyl-methylamine-and 1,2-dimethylhydrazine-induced colonic tumors in rats: monotherapy with 5-fluorouracil, ftorafur, CGP 6809, and CGP 15'720A. J Cancer Res Clin Oncol. 1982;104(1-2):115-31. PubMed PMID: 6813336.